{"id":"induction-cycles-a1-a3","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"50-70%","effect":"Fatigue"},{"rate":"80-100%","effect":"Hair loss"},{"rate":"10-30%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This regimen involves a series of chemotherapy cycles to prepare the patient for transplantation, with the goal of inducing a state of remission or reducing the risk of complications during the transplant process.","oneSentence":"Induction Cycles A1-A3 is a treatment regimen for patients undergoing hematopoietic stem cell transplantation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:26.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT05735184","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-07-18","conditions":"Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML","enrollment":420},{"nctId":"NCT05453903","phase":"PHASE1","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":196},{"nctId":"NCT05361733","phase":"PHASE1","title":"A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.","status":"NOT_YET_RECRUITING","sponsor":"Xfibra, Inc.","startDate":"2026-01-15","conditions":"Focus of the Study: Safety of XFB19","enrollment":40},{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96},{"nctId":"NCT05025397","phase":"PHASE1","title":"A Study of Danavorexton in Anesthetized Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-09-28","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT04422210","phase":"PHASE1","title":"A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-22","conditions":"Small Cell Lung Cancer","enrollment":2},{"nctId":"NCT02892318","phase":"PHASE1","title":"A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-10-31","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT03018405","phase":"PHASE1, PHASE2","title":"A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications","status":"UNKNOWN","sponsor":"Celyad Oncology SA","startDate":"2016-12","conditions":"Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)","enrollment":146},{"nctId":"NCT01160354","phase":"PHASE1, PHASE2","title":"Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08","conditions":"Acute Myelogenous Leukemia","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Induction Cycles A1-A3","genericName":"Induction Cycles A1-A3","companyName":"Nationwide Children's Hospital","companyId":"nationwide-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Induction Cycles A1-A3 is a treatment regimen for patients undergoing hematopoietic stem cell transplantation. Used for Hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}